Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:ORMP's Cash to Debt is ranked higher than
87% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:ORMP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:ORMP' s Cash to Debt Range Over the Past 10 Years
Min: 1.06  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.85
NAS:ORMP's Equity to Asset is ranked higher than
74% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ORMP: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ORMP' s Equity to Asset Range Over the Past 10 Years
Min: 0.85  Med: 0.85 Max: 0.85
Current: 0.85
F-Score: 4
Z-Score: 10.06
WACC vs ROIC
6.42%
-45.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -3001.39
NAS:ORMP's Operating margin (%) is ranked lower than
85% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:ORMP: -3001.39 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ORMP' s Operating margin (%) Range Over the Past 10 Years
Min: -3001.39  Med: 0 Max: 0
Current: -3001.39
-3001.39
0
Net-margin (%) -2888.89
NAS:ORMP's Net-margin (%) is ranked lower than
85% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:ORMP: -2888.89 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ORMP' s Net-margin (%) Range Over the Past 10 Years
Min: -2888.89  Med: 0 Max: 0
Current: -2888.89
-2888.89
0
ROE (%) -31.42
NAS:ORMP's ROE (%) is ranked higher than
51% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:ORMP: -31.42 )
Ranked among companies with meaningful ROE (%) only.
NAS:ORMP' s ROE (%) Range Over the Past 10 Years
Min: -8090  Med: -75.21 Max: -31.42
Current: -31.42
-8090
-31.42
ROA (%) -28.29
NAS:ORMP's ROA (%) is ranked lower than
51% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:ORMP: -28.29 )
Ranked among companies with meaningful ROA (%) only.
NAS:ORMP' s ROA (%) Range Over the Past 10 Years
Min: -468.93  Med: -66.23 Max: -28.29
Current: -28.29
-468.93
-28.29
ROC (Joel Greenblatt) (%) -72.49
NAS:ORMP's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:ORMP: -72.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ORMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -313200  Med: -293.24 Max: 5234
Current: -72.49
-313200
5234
EBITDA Growth (3Y)(%) 11.00
NAS:ORMP's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:ORMP: 11.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ORMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 5.6 Max: 57.2
Current: 11
-10.7
57.2
EPS Growth (3Y)(%) 5.50
NAS:ORMP's EPS Growth (3Y)(%) is ranked higher than
61% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. NAS:ORMP: 5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ORMP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.3  Med: 2.45 Max: 188.4
Current: 5.5
-26.3
188.4
» NAS:ORMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PHGUF, NAS:KIN, NAS:ONS, NAS:QLTI, NAS:AKTX, AMEX:CRMD, NAS:EIGR, NAS:CRME, NAS:FATE, NAS:PPHM, NAS:SBPH, OTCPK:RCAR, OTCPK:CLALF, OTCPK:OXBDF, NAS:AFMD, NAS:VBLT, NAS:CFRX, NAS:GTXI, NAS:CTIC, AMEX:XXII » details
Traded in other countries:OJU1.Germany, ORMP.Switzerland,
Oramed Pharmaceuticals Inc is a pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.

Oramed Pharmaceuticals Inc was incorporated on April 12, 2002, under the laws of the state of Nevada. It is a pharmaceutical company engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. It filed two additional provisional patents for a suppository application to its technology portfolio. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.

Ratios

vs
industry
vs
history
P/B 3.07
ORMP's P/B is ranked higher than
56% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ORMP: 3.07 )
Ranked among companies with meaningful P/B only.
ORMP' s P/B Range Over the Past 10 Years
Min: 2.44  Med: 3.34 Max: 3.77
Current: 3.07
2.44
3.77
P/S 331.80
ORMP's P/S is ranked lower than
92% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. ORMP: 331.80 )
Ranked among companies with meaningful P/S only.
ORMP' s P/S Range Over the Past 10 Years
Min: 330.45  Med: 379.55 Max: 930
Current: 331.8
330.45
930
Current Ratio 18.79
ORMP's Current Ratio is ranked higher than
92% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. ORMP: 18.79 )
Ranked among companies with meaningful Current Ratio only.
ORMP' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 8.19 Max: 67.68
Current: 18.79
0.13
67.68
Quick Ratio 18.79
ORMP's Quick Ratio is ranked higher than
92% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ORMP: 18.79 )
Ranked among companies with meaningful Quick Ratio only.
ORMP' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 8.19 Max: 67.68
Current: 18.79
0.13
67.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.10
ORMP's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ORMP: -20.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ORMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -44.9  Med: -18.7 Max: -7.6
Current: -20.1
-44.9
-7.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 73.00
ORMP's Price/Net Cash is ranked lower than
96% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. ORMP: 73.00 )
Ranked among companies with meaningful Price/Net Cash only.
ORMP' s Price/Net Cash Range Over the Past 10 Years
Min: 2.58  Med: 12.29 Max: 139.2
Current: 73
2.58
139.2
Price/Net Current Asset Value 4.83
ORMP's Price/Net Current Asset Value is ranked higher than
55% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. ORMP: 4.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ORMP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.56  Med: 7.77 Max: 94.5
Current: 4.83
2.56
94.5
Price/Tangible Book 3.09
ORMP's Price/Tangible Book is ranked higher than
64% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. ORMP: 3.09 )
Ranked among companies with meaningful Price/Tangible Book only.
ORMP' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.19  Med: 7.41 Max: 76.36
Current: 3.09
2.19
76.36
Price/Projected FCF 10.74
ORMP's Price/Projected FCF is ranked lower than
78% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. ORMP: 10.74 )
Ranked among companies with meaningful Price/Projected FCF only.
ORMP' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.46  Med: 10.1 Max: 18.2
Current: 10.74
5.46
18.2
Price/Median PS Value 0.87
ORMP's Price/Median PS Value is ranked higher than
56% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. ORMP: 0.87 )
Ranked among companies with meaningful Price/Median PS Value only.
ORMP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.87  Med: 1.46 Max: 1.87
Current: 0.87
0.87
1.87
Earnings Yield (Greenblatt) (%) -9.28
ORMP's Earnings Yield (Greenblatt) (%) is ranked higher than
50% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ORMP: -9.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ORMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -666.7  Med: 0 Max: 9.3
Current: -9.28
-666.7
9.3

More Statistics

Revenue (TTM) (Mil) $0.29
EPS (TTM) $ -0.69
Beta0.62
Short Percentage of Float4.35%
52-Week Range $5.46 - 10.74
Shares Outstanding (Mil)13.14

Analyst Estimate

Aug16 Aug17 Aug18
Revenue (Mil $) 0 1 1
EPS ($) -0.67 -0.61 -1.01
EPS w/o NRI ($) -0.67 -0.61 -1.01
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ORMP

Headlines

Articles On GuruFocus.com

More From Other Websites
Oramed to Present at the Aegis Capital Growth Conference Sep 19 2016
Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes,... Sep 09 2016
Oramed to Present at the Rodman & Renshaw Global Investment Conference Sep 07 2016
Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO)... Sep 06 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 31 2016
Oramed (ORMP) Reports Additional Positive Data from Phase IIb ORMD-0801 Study Aug 11 2016
The Cryptic World of Oral Insulin, Novo Nordisk A/S (ADR) (NVO) vs Oramed Pharmaceuticals, Inc.... Aug 09 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 05 2016
Oramed Receives Additional $4 Million Milestone Payment From HTIT Aug 02 2016
Oramed Receives Additional $4 Million Milestone Payment From HTIT Aug 02 2016
Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of... Jul 28 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events Jul 28 2016
Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of... Jul 28 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 27 2016
Oramed Appoints Dr. Roy Eldor as Chief Medical Director Jul 26 2016
Oramed Appoints Dr. Roy Eldor as Chief Medical Director Jul 26 2016
ORAMED PHARMACEUTICALS INC. Financials Jul 12 2016
Oramed reports 3Q loss Jul 06 2016
Oramed reports 3Q loss Jul 06 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jul 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)